25 Stocks That Billionaires Own

Studying the kind of assets that billionaires put their own capital into is always a worthwhile endeavor. And while you don't need to track every trading Market News [Financhill] Smart Trading. Simplified. [Is this Killer new EXTRA INCOME strategy the Best Side Hustle EVER?](~/AACAmgA~/RgRja92JP0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTc2OSZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEE1T0NaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXpNamc9VwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Have you seen this new extra-income hack yet? Everyday Americans have been making 100%, 200%, 500%, or more... sometimes in a matter of days with this one new strategy. Some of them are retiring from their jobs because of it. Others have paid off all their debt and bought their dream homes. [You can see their stories for yourself right here.](~/AACAmgA~/RgRja92JP0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTc2OSZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEE1T0NaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXpNamc9VwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Sponsored 25 Stocks That Billionaires Own Studying the kind of assets that billionaires put their own capital into is always a worthwhile endeavor. And while you don’t need to track every trading decision of the world’s richest investors, it’s never a bad idea to see where the general flow of money is going. In this article we’ll look at 25 top […] [Continue Reading >](~/AACAmgA~/RgRja92JP0RCaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9zdG9ja3MtdGhhdC1iaWxsaW9uYWlyZXMtb3duVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Small Biotech Could Soar 1,000%](~/AACAmgA~/RgRja92JP0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTY3MiZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEkxTnlaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXlOekk9VwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) There's no sector poised to deliver bigger gains in 2021 than small-cap biotech stocks. In the past year alone... Novavax Inc jumped from $6.26 to $270.51, a gain of 3,396%. Aclaris Therapts jumped from $0.70 to $24.28 an increase of 1,583%. Vaxart Inc rocketed from $0.97 to $14.94, a 1,083% jump. [Here's the next biotech we think could soar 1,000% ](~/AACAmgA~/RgRja92JP0ScaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTY3MiZhZD1hSFIwY0hNNkx5OXBiWE53ZFdKc2FYTm9aWEpuY205MWNDNW5iekpqYkc5MVpDNXZjbWN2WVdabVgyTS9iMlptWlhKZmFXUTlOVEkxTnlaaFptWmZhV1E5TVRFMU5DWm1hV3hsWDJsa1BUSXlOekk9VwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) Sponsored Is Zomedica Overvalued Is Zomedica stock overvalued? Zomedica shares soared near the beginning of 2021, but then plummeted over 80% from their highest share price. In retrospect, it seems like shareholders had pie-in-the-sky dreams for Truforma, the company’s point-of-care diagnostic system. Hopes were that the diagnostic system would gain fast traction, but it never materialized – by July […] [Continue Reading >](~/AACAmgA~/RgRja92JP0RCaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9pcy16b21lZGljYS1zdG9jay1vdmVydmFsdWVkVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [The $62.7 Billion Medical "Gold Rush"](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODImYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME55WmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RjPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) A small San Francisco company holds the secret to a medical breakthrough The Economist called "A Boon to Humanity?" Jim Cramer says it would be "The Biggest Drug Ever." And our research proves that anyone who gets in now could profit 8990% [Click Here to Learn How ](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODImYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME55WmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RjPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored Is It Too Late To Buy VOO? For retail investors and traders, exchange-traded funds — or ETFs — can prove to be a great alternative to traditional stock market investments. Not only are ETFs simple to invest in and manage, ETFs can also generate an impressive return with very little investment or effort involved. This is to some extent because exchange […] [Continue Reading >](~/AACAmgA~/RgRja92JP0Q_aHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9pcy1pdC10b28tbGF0ZS10by1idXktdm9vVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Tiny Biotech Wins $75 Billion Patent](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME1pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RJPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Cambridge firm proves its possible to "Find & Replace" cancer cells. The Wall Street Journal reports this small biotech is "Transforming Medicine." No wonder Goldman Sachs & Morgan Stanley have been quietly buying shares. [Get the name of this little-known stock here ](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME1pWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RJPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored Is It Too Late To Buy MercadoLibre? Latin America’s smartphone market grew 22.1 percent year-over-year in the first quarter of 2021, and it grew 41.8 percent year-over-year in the second quarter of 2021. Analysts are projecting that Latin Americans will buy a total of 134.3 million smartphones in 2021 alone. A growing middle class with access to mobile technology create the right […] [Continue Reading >](~/AACAmgA~/RgRja92JP0RIaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9pcy1pdC10b28tbGF0ZS10by1idXktbWVyY2Fkb2xpYnJlVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~) [Our #1 Investment of 2021](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODUmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME5DWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RRPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) In August 2019, a small firm won a contract from the US Army to build a strange new weapon. When it starts producing this amazing weapon in scale later this year, the company could multiply its revenue 1,632-fold. [Our research proves that anyone who gets in now could profit 8990% ](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTEyODUmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpjME5DWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk1T0RRPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored 1 Metric That Forecasts Bitcoin $100,000 The cryptocurrency market, much like the stock market, experiences price fluctuations because of two things – supply & demand. When there’s more supply and less demand (aka more sellers than buyers), market prices drop. It doesn’t matter if you’re talking stocks or crypto coins – when supply is up and demand is down, prices follow […] [Continue Reading >](~/AACAmgA~/RgRja92JP0RSaHR0cHM6Ly9maW5hbmNoaWxsLmNvbS9ibG9nL2ludmVzdGluZy9zdG9jay10by1mbG93LWZvcmVjYXN0cy1iaXRjb2luLXByaWNlLTEwMDAwMFcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) [Tiny Biotech Creates $2 Trillion Drug](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExMzYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpRME5TWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0TXpFPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) The Wall Street Journal reports new treatment is "transforming medicine." Bill Gates writes that it could "help humanity." Ark Investments think it could be a "$2 trillion market." And one small company owns the patent on it. [This unknown biotech's stock is set to surge 46,751% ](~/AACAmgA~/RgRja92JP0SdaHR0cDovL2ZpbmFuY2hpbGwuY29tL2FkP3R5cGU9aW1zJmlkPTExMzYmYWQ9YUhSMGNITTZMeTlwYlhOd2RXSnNhWE5vWlhKbmNtOTFjQzVuYnpKamJHOTFaQzV2Y21jdllXWm1YMk0vYjJabVpYSmZhV1E5TmpRME5TWmhabVpmYVdROU1URTFOQ1ptYVd4bFgybGtQVEk0TXpFPVcDc3BjQgphiQ9ZiWFR1PWiUht0cmlzdHJhbWJhbGR3aW44OEBnbWFpbC5jb21YBAAAAAA~) Sponsored View this email [online](~/AACAmgA~/RgRja92JP0QaaHR0cDovL2ZpbmFuY2hpbGwuY29tL2Jsb2dXA3NwY0IKYYkPWYlhUdT1olIbdHJpc3RyYW1iYWxkd2luODhAZ21haWwuY29tWAQAAAAA) if it doesn't display correctly. This newsletter is not financial advice. Please read our [Disclaimer](~/AACAmgA~/RgRja92JP0QbaHR0cDovL2ZpbmFuY2hpbGwuY29tL3Rlcm1zVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). To unsubscribe from Financhill, [click here](~/AACAmgA~/RgRja92JP0RRaHR0cDovL2ZpbmFuY2hpbGwuY29tL3Vuc3Vic2NyaWJlL2U4YmZlNTA1YTg4ODRjNGI3YWU3ZmQzMWEyYmIzNjhkLTQ1MzkxNjAwLTg2OTE1VwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). PO Box 126 Catasauqua, PA 18032 Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. The sender of this email makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity's compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email. The content on any of Financhill websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: [Characteristics and Risks of Standardized Options](~/AACAmgA~/RgRja92JP0RFaHR0cDovL3d3dy5vcHRpb25zY2xlYXJpbmcuY29tL2Fib3V0L3B1YmxpY2F0aW9ucy9jaGFyYWN0ZXItcmlza3MuanNwVwNzcGNCCmGJD1mJYVHU9aJSG3RyaXN0cmFtYmFsZHdpbjg4QGdtYWlsLmNvbVgEAAAAAA~~). The Financhill.com educational training program and software services are provided to improve financial understanding. The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing. Past performance is no guarantee of future performance. This product is for educational purposes only. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. Any trades shown are hypothetical example and do not represent actual trades. Actual results may differ. Nothing here in constitutes a recommendation respecting the particular security illustrated.